Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Shell Asset Management Co.

Shell Asset Management Co. lessened its holdings in shares of Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 12.9% during the 1st quarter, Holdings Channel reports. The firm owned 1,958 shares of the health services provider’s stock after selling 289 shares during the period. Shell Asset Management Co.’s holdings in Amedisys were worth $337,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Mackenzie Financial Corp increased its stake in shares of Amedisys by 39,235.8% during the fourth quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock worth $92,331,000 after buying an additional 568,919 shares during the period. Bellevue Group AG increased its stake in shares of Amedisys by 61.8% during the fourth quarter. Bellevue Group AG now owns 490,012 shares of the health services provider’s stock worth $79,323,000 after buying an additional 187,214 shares during the period. Schroder Investment Management Group increased its stake in shares of Amedisys by 937.3% during the fourth quarter. Schroder Investment Management Group now owns 187,883 shares of the health services provider’s stock worth $30,415,000 after buying an additional 169,770 shares during the period. Frontier Capital Management Co. LLC increased its stake in shares of Amedisys by 98.3% during the first quarter. Frontier Capital Management Co. LLC now owns 340,741 shares of the health services provider’s stock worth $58,706,000 after buying an additional 168,949 shares during the period. Finally, First Trust Advisors LP increased its stake in shares of Amedisys by 235.6% during the fourth quarter. First Trust Advisors LP now owns 151,640 shares of the health services provider’s stock worth $24,547,000 after buying an additional 106,453 shares during the period. Institutional investors and hedge funds own 90.47% of the company’s stock.

Wall Street Analysts Forecast Growth

AMED has been the topic of a number of recent research reports. SVB Leerink cut their target price on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating on the stock in a research note on Tuesday, June 21st. Stifel Nicolaus assumed coverage on shares of Amedisys in a research note on Tuesday, June 28th. They issued a “hold” rating and a $128.00 price target on the stock. Truist Financial dropped their price target on shares of Amedisys from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Thursday, July 14th. Stephens dropped their price target on shares of Amedisys from $155.00 to $125.00 and set an “equal weight” rating on the stock in a research note on Tuesday, June 21st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $200.00 price target on shares of Amedisys in a research note on Tuesday, June 28th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $160.63.

Amedisys Price Performance

Shares of NASDAQ AMED opened at $121.17 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.92 and a quick ratio of 0.92. The stock has a fifty day moving average price of $118.38 and a 200 day moving average price of $134.64. Amedisys, Inc. has a 1-year low of $101.61 and a 1-year high of $203.84. The company has a market cap of $3.93 billion, a PE ratio of 28.24, a P/E/G ratio of 2.39 and a beta of 0.95.

Amedisys (NASDAQ:AMEDGet Rating) last issued its quarterly earnings results on Wednesday, July 27th. The health services provider reported $1.47 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.24. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. The firm had revenue of $557.89 million during the quarter, compared to the consensus estimate of $583.12 million. During the same period last year, the company earned $1.69 earnings per share. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. Sell-side analysts forecast that Amedisys, Inc. will post 5.35 EPS for the current year.

Insider Buying and Selling at Amedisys

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of the firm’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total value of $64,055.00. Following the completion of the sale, the insider now owns 11,850 shares of the company’s stock, valued at $1,362,750. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.10% of the stock is owned by corporate insiders.

Amedisys Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.